ADGM Adagio Medical Holdings, Inc Common Stock
XNASStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
ADGM
—
—
Key stats
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $0.0B
- Employees
- 41
- List Date
- 2024-08-01
- CIK
- 0002006986
- Next Earnings
- 2026-11-11
- EPS Forecast
- ($0.30) (1 est.)
- Headquarters
- Laguna Hills, CA
- Homepage
- https://www.adagiomedical.com
Adagio Medical Holdings Inc is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias with its proprietary, catheter-based Ultra-Low Temperature Ablation (ULTA) technology. UTLA is designed to create large, durable lesions extending through the depth of both diseased and healthy cardiac tissue. The company is currently focused on the treatment of ventricular tachycardia (VT), a rapid, abnormal heart rhythm, or arrhythmia, that originates in the heart's lower chambers, or ventricles. The company has one reportable segment.
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '24 | '25 | '26 | Avg |
|---|---|---|---|---|
| Jan | -- | 0.00% | -7.41% | -3.71% |
| Feb | -- | -32.85% | -2.91% | -17.88% |
| Mar | -- | -15.63% | 10.58% | -2.53% |
| Apr | -- | 53.57% | -23.05% | 15.26% |
| May | -- | -10.32% | -29.71% | -20.02% |
| Jun | -- | 15.04% | -15.37% | -0.17% |
| Jul | -- | -2.22% | -41.80% | -22.01% |
| Aug | -43.09% | 27.78% | 14.87% | -0.15% |
| Sep | -46.80% | 18.29% | -70.14% | -32.88% |
| Oct | -3.71% | -42.42% | -38.01%* | -28.05% |
| Nov | -1.66% | -26.41% | -- | -14.04% |
| Dec | -57.49% | 7.02% | -- | -25.23% |
| Total | -87.81% | -39.84% | -94.37% | -74.01% |
* Only 3 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $0.12
SMA 50: $0.35
SMA 200: $0.77
Current: $0.10
EMA 12: $0.12
EMA 26: $0.19
MACD: -0.0685 | Signal: 0.0132
BEARISH
ADX (14): 47.68
STRONG TREND
+DI: 11.41
−DI: 37.26
Momentum Oscillators
RSI (14): 25.71
OVERSOLD
Stoch %K: 30.69
Stoch %D: 35.95
Williams %R: -76.70
Volume & Volatility
BB Upper: $0.16
BB Lower: $0.09
NEUTRAL
OBV: 575,001,055
Vol SMA 20: 2,860,620
Vol ROC: -51.01%
ATR: $0.03
True Range: $0.02
HV 20: 170.5%
HV 30: 259.4%
HV 60: 233.1%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis
LLM Stock Analysis Report: ADGM
Executive Summary
Overall assessment: BEARISH (Confidence level: 6/10)
Key drivers:
- Bearish momentum signals from MACD histogram
- Oversold RSI reading
- Negative news sentiment from recent headlines
- High volatility and beta indicating a high-risk profile
Primary risks:
- Technical breakdown below $0.68 support
- Earnings miss or negative guidance
- Regulatory issues or clinical trial setbacks
Investment thesis: ADGM's recent price decline is driven by bearish momentum signals and oversold RSI reading. The stock's high volatility and beta suggest a high-risk profile, making it challenging to predict its next move.
Recent news sentiment impact: The positive headline about Adagio Medical's Heart Ablation System shows 84% freedom from shock has a neutral impact on the analysis, as it is not directly related to ADGM's recent price decline.
Technical Analysis
Trend Direction: Short-term (1-4 weeks) and Medium-term (1-3 months) are bearish. Long-term (3-12 months) is neutral due to recent price declines.
Support/Resistance Levels:
- Resistance: $0.80 (SMA 20)
- Support: $0.68 (Lower Bollinger Band)
Momentum Signals:
- RSI interpretation: Oversold (<30), indicating potential buying opportunity
- MACD signal: Bearish, suggesting further price decline
- Bollinger Bands position: Mean reversion, indicating a potential bounce
Volume Analysis: Volume trends suggest institutional interest is decreasing.
News & Sentiment Analysis
Recent Headlines Summary: Two recent headlines were analyzed, one positive and one neutral. The positive headline about Adagio Medical's Heart Ablation System shows 84% freedom from shock has a neutral impact on the analysis.
Sentiment Assessment: Overall sentiment is NEUTRAL due to mixed news and lack of significant market-moving events.
Catalyst Identification: None identified in recent headlines, but upcoming earnings reports or product launches could be potential catalysts.
Market Narrative: The news aligns with the bearish technical signals, suggesting a continued price decline unless a positive catalyst emerges.
Risk & Volatility Assessment
Beta Interpretation: ADGM's beta of 1.23 suggests high risk relative to the market.
Volatility Regime: High volatility is ongoing, making it challenging to predict short-term movements.
Options Market Signals: No options data available for analysis.
Downside Protection: Support levels and risk management considerations are crucial due to the stock's high-risk profile.
Market Context & Positioning
Sector Performance: ADGM's performance is weak compared to its sector.
Institutional Activity: Decreasing institutional interest suggests a potential reversal or continued price decline.
Correlation Analysis: ADGM's correlation with the market (R-squared) is 0.13, indicating a low degree of movement relative to the broader market.
Relative Valuation: The stock's position within its trading range is challenging to determine due to recent volatility and lack of significant news catalysts.
Key Levels & Action Items
Critical Price Levels:
- Support: $0.68 (Lower Bollinger Band)
- Resistance: $0.80 (SMA 20)
Breakout/Breakdown Levels: None identified, but a potential breakout above $0.91 or breakdown below $0.68 could trigger significant moves.
Time-Sensitive Catalysts: Earnings reports or product launches could be potential catalysts in the near term.
Risk Management: Consider stop-loss levels at $0.60 and position sizing considerations due to the stock's high-risk profile.
Please note that this is a sample report, and actual data should be used for analysis purposes.
Generated
News
All ADGM news →
Earnings History
1 of 1 under expected move
Avg Expected Move
—
Avg Actual Move
0.01%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-08-12 | unknown | — | 0.01% | — | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
ADGM Options Activity & IV Rank
Loading options activity...
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
Risk Metrics
Beta: 2.1365
Alpha: -187.12%
Correlation: 0.1890
R-Squared: 3.6%
Stock Volatility: 144.1%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own ADGM
1 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Citadel Hedge fund Ken Griffin | $11K | #6225 of 6285 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
ADGM Institutional Ownership (13F)
Latest filings — 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
ADGM Insider Trading (Form 4)
Latest: 2026-10-13Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-13 | Keyvan Mirsaeedi-Farahani | Director | Other (J) | +12,770 | — | EDGAR | |
| 2026-08-12 | Timothy P. Moran | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-08-12 | Sandra A. Gardiner | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-08-12 | Keyvan Mirsaeedi-Farahani | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-08-12 | Orly Mishan | Director | Grant (A) | +100,000 opt | — | EDGAR | |
| 2026-08-12 | Sean Salmon | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-08-12 | James L Cox | Director | Grant (A) | +30,000 opt | — | EDGAR | |
| 2026-03-09 | Todd Usen | Chief Executive Officer | Grant (A) | +800,000 opt | — | EDGAR | |
| 2026-03-09 | Deborah Kaster | Chief Financial Officer | Grant (A) | +490,500 opt | — | EDGAR | |
| 2025-12-18 | Deborah Kaster | Chief Financial Officer | Buy (P) | +15,000 | $1.20 | $18.0K | EDGAR |
| 2025-12-15 | Todd Usen | Chief Executive Officer | Buy (P) | +207,315 | $1.09 | $226.0K | EDGAR |
| 2025-12-11 | Sean Salmon | Director | Grant (A) | +90,000 opt | — | EDGAR | |
| 2025-10-22 | Joseph Edelman | 10%+ Owner | Buy (P) | +18,676,479 RSU | — | EDGAR | |
| 2025-03-21 | Orly Mishan | Director | Grant (A) | +300,000 opt | — | EDGAR | |
| 2025-03-21 | Sandra A. Gardiner | Director | Grant (A) | +90,000 opt | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
ADGM Insider Holdings
5 insiders · @ $0.10
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | PERCEPTIVE ADVISORS LLC | Director | 9,876,586 | $955.1K | $0 | 1 | 2025-02-14 |
| 2 | Todd Usen | Chief Executive Officer | 207,315 | $20.0K | $226.0K | 3 | 2026-03-09 |
| 3 | James L Cox | Director | 36,698 | $3.5K | $0 | 3 | 2026-08-12 |
| 4 | Deborah Kaster | Chief Financial Officer | 15,000 | $1.5K | $18.0K | 2 | 2026-03-09 |
| 5 | Keyvan Mirsaeedi-Farahani | Director | 12,770 | $1.2K | $0 | 3 | 2026-10-13 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ADGM Board & Officers
As of SEC filings through Oct 13, 2026Directors 8
- James L Cox · since Jul 31, 2024
- Keyvan Mirsaeedi-Farahani · since Jul 31, 2024
- Orly Mishan · since Jul 31, 2024
- Perceptive Advisors LLC (entity) · since Jul 31, 2024
- Sandra A. Gardiner · since Jul 31, 2024
- Timothy P. Moran · since Jul 31, 2024
- Todd Usen · since Dec 13, 2024
- Sean Salmon · since Dec 11, 2025
Officers 2
- Todd Usen · Chief Executive Officer · since Dec 13, 2024
- Deborah Kaster · Chief Financial Officer · since Sep 5, 2025
10% owners 3
- Joseph Edelman · since Jul 31, 2024
- Perceptive Advisors LLC (entity) · since Jul 31, 2024
- Perceptive Life Sciences Master Fund Ltd (entity) · since Jul 31, 2024
Changes in the last 10 years (34)
| Dec 11, 2025 | Sean Salmon became a director |
| Sep 5, 2025 | Deborah Kaster became Chief Financial Officer |
| Sep 3, 2025 | The company announced the departure of Dan George as Interim CFO in an SEC filing |
| Apr 17, 2025 | Dan George became Interim CFO |
| Mar 11, 2025 | The company announced the departure of John T Dahldorf as Chief Financial Officer in an SEC filing |
| Feb 28, 2025 | The company announced the departure of Hakon Bergheim as Chief Operating Officer in an SEC filing |
| Feb 14, 2025 | Perceptive Life Sciences Master Fund Ltd first listed as a director in an SEC filing |
| Feb 14, 2025 | Joseph Edelman first listed as a director in an SEC filing |
| Feb 14, 2025 | C2 Life Sciences LLC first on file as a director |
| Feb 14, 2025 | C2 Life Sciences LLC first on file as a 10% owner |
| Dec 19, 2024 | The company announced the departure of Shahram Moaddeb from the board in an SEC filing |
| Dec 13, 2024 | Todd Usen became a director |
| Dec 13, 2024 | Todd Usen became Chief Executive Officer |
| Dec 11, 2024 | The company announced the departure of Olav Bergheim as CEO and Chairman in an SEC filing |
| Oct 1, 2024 | Michael Seth Altman reported in an SEC filing no longer being a 10% owner |
| Oct 1, 2024 | Adam Leo Stone reported in an SEC filing no longer being a 10% owner |
| Oct 1, 2024 | ARYA Sciences Holdings IV reported in an SEC filing no longer being a 10% owner |
| Jul 31, 2024 | Timothy P. Moran became a director |
| Jul 31, 2024 | Shahram Moaddeb became a director |
| Jul 31, 2024 | Sandra A. Gardiner became a director |
| Jul 31, 2024 | Perceptive Life Sciences Master Fund Ltd became a 10% owner |
| Jul 31, 2024 | Perceptive Advisors LLC became a director |
| Jul 31, 2024 | Perceptive Advisors LLC became a 10% owner |
| Jul 31, 2024 | Orly Mishan became a director |
| Jul 31, 2024 | Olav Bergheim became a director |
| Jul 31, 2024 | Olav Bergheim became CEO and Chairman |
| Jul 31, 2024 | Michael Seth Altman became a 10% owner |
| Jul 31, 2024 | Keyvan Mirsaeedi-Farahani became a director |
| Jul 31, 2024 | Joseph Edelman became a 10% owner |
| Jul 31, 2024 | John T Dahldorf became Chief Financial Officer |
| Jul 31, 2024 | James L Cox became a director |
| Jul 31, 2024 | Hakon Bergheim became Chief Operating Officer |
| Jul 31, 2024 | Adam Leo Stone became a 10% owner |
| Jul 31, 2024 | ARYA Sciences Holdings IV became a 10% owner |
Not reported recently (2)
- C2 Life Sciences LLC · Last reported as a director in an SEC filing dated Feb 14, 2025
- Olav Bergheim · Last reported as a director in an SEC filing dated Aug 2, 2024
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
ETF Holders
2 ETFs hold ADGM
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.